Form 4 for LXEO Lexeo Therapeutics, Inc.
Accepted 2026-04-07 16:55:07 ET · period of report 2026-04-06 · accession 0001995218-26-000009 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-04-07 16:55 | 2026-04-06 | LXEO | Townsend Richard Nolan | CEO, Dir | S - Sale | $5.69 | -55.0K | 340.1K | -14% | -$313.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-06 | S | D | 55,000 | $5.69 | 340,106 | D | — | — | (F1) The sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025. (F2) This transaction was executed in multiple trades at prices ranging from $5.56 to $5.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F3) Includes 261,349 Restricted Stock Units (RSU's). Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. |